Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten

Company Sees Opportunity For A Similar Ramp-Up For The Cardiovascular Drug

Executive Summary

Paying $13.1bn for MyoKardia and its potential first-in-class HCM drug, BMS sees a blockbuster sales opportunity that it will grow gradually. MyoKardia team will be absorbed into BMS, Caforio says.

You may also be interested in...



Merck Closes In On Acceleron But BMS And Anti-Trust Regulators Could Be Obstacles

Biopharma M&A has had a quiet year so far but could heat up if rivals start vying for the biotech company.

Cardior Counts On RNA To Tackle Cardiac Disease

The German firm intends to use the proceeds from an over-subscribed round to move its micro-RNA-132 inhibitor forward into trials for heart failure and advance its pipeline.

Cytokinetics’ CK-274 Appears To Upstage BMS’s Newly Acquired Mavacamten

The REDWOOD-HCM study showed early, sustained efficacy and no serious adverse events with a drug Cytokinetics designed to be superior to mavacamten, a drug it spun out via BMS-acquired MyoKardia.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel